Updated Jul 16, 2026
O'Neill Gilmore Neil has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $82K.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-05 | EDIT | Editas Medicine, Inc. | S — Open-market sale | 15.4K | $2.70 | $42K |
| 2026-03-04 | EDIT | Editas Medicine, Inc. | S — Open-market sale | 5.4K | $2.02 | $11K |
| 2025-12-04 | EDIT | Editas Medicine, Inc. | S — Open-market sale | 5.6K | $2.15 | $12K |
| 2025-09-03 | EDIT | Editas Medicine, Inc. | S — Open-market sale | 5.6K | $2.60 | $15K |
| 2024-12-05 | EDIT | Editas Medicine, Inc. | S — Open-market sale | 1.6K | $2.08 | $3K |
O'Neill Gilmore Neil is a corporate insider — currently tracked as CEO, Director of Editas Medicine, Inc. (EDIT). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($82K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live O'Neill Gilmore Neil profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.